Product: ACSL4/FACL4 Antibody
Catalog: DF12141
Source: Rabbit
Application: WB, IHC, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 79 kDa,74 kDa; 79kD(Calculated).
Uniprot: O60488
RRID: AB_2844946

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(83%)
ACSL4/FACL4 Antibody detects endogenous levels of total ACSL4/FACL4.
Cite Format: Affinity Biosciences Cat# DF12141, RRID:AB_2844946.
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.


ACS 4; ACS4; ACSL 4; Acsl4; ACSL4_HUMAN; acyl CoA synthetase 4; Acyl CoA synthetase long chain family member 4; FACL 4; FACL4; Fatty acid Coenzyme A ligase; fatty acid Coenzyme A ligase long-chain 4; LACS 4; LACS4; Lignoceroyl CoA synthase; Long chain 4; long chain acyl CoA synthetase 4; long chain fatty acid CoA ligase 4; long chain fatty acid Coenzyme A ligase 4; Long-chain acyl-CoA synthetase 4; Long-chain-fatty-acid--CoA ligase 4; MRX63; MRX68;





Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O60488 As Substrate

Site PTM Type Enzyme
S23 Phosphorylation
Y31 Phosphorylation
T34 Phosphorylation
K47 Ubiquitination
K49 Ubiquitination
K54 Ubiquitination
S57 Phosphorylation
T63 Phosphorylation
K89 Acetylation
K89 Ubiquitination
K92 Acetylation
S95 Phosphorylation
K113 Ubiquitination
K117 Ubiquitination
S140 Phosphorylation
T143 Phosphorylation
K148 Ubiquitination
K150 Ubiquitination
K211 Ubiquitination
C221 S-Nitrosylation
K223 Ubiquitination
Y227 Phosphorylation
K231 Ubiquitination
K312 Ubiquitination
S352 Phosphorylation
S353 Phosphorylation
K354 Ubiquitination
K356 Ubiquitination
K360 Ubiquitination
K367 Ubiquitination
K383 Ubiquitination
K388 Ubiquitination
K397 Acetylation
K397 Ubiquitination
K401 Acetylation
K401 Ubiquitination
Y404 Phosphorylation
K407 Ubiquitination
K413 Ubiquitination
Y415 Phosphorylation
K426 Ubiquitination
S447 Phosphorylation
Y483 Phosphorylation
T485 Phosphorylation
K498 Ubiquitination
K500 Ubiquitination
T508 Phosphorylation
K512 Ubiquitination
K536 Ubiquitination
Y541 Phosphorylation
Y582 Phosphorylation
S584 Phosphorylation
K587 Ubiquitination
K593 Ubiquitination
S607 Phosphorylation
K621 Ubiquitination
K651 Ubiquitination
K661 Ubiquitination
K670 Ubiquitination
S674 Phosphorylation
T679 Phosphorylation
T682 Phosphorylation
T686 Phosphorylation
K690 Acetylation
K690 Ubiquitination
K702 Ubiquitination

Research Backgrounds


Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoA for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially activates arachidonate and eicosapentaenoate as substrates. Preferentially activates 8,9-EET > 14,15-EET > 5,6-EET > 11,12-EET. Modulates glucose-stimulated insulin secretion by regulating the levels of unesterified EETs (By similarity). Modulates prostaglandin E2 secretion.

Subcellular Location:

Mitochondrion outer membrane>Single-pass type III membrane protein. Peroxisome membrane>Single-pass type III membrane protein. Microsome membrane>Single-pass type III membrane protein. Endoplasmic reticulum membrane>Single-pass type III membrane protein. Cell membrane.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location

Belongs to the ATP-dependent AMP-binding enzyme family.

Research Fields

· Cellular Processes > Transport and catabolism > Peroxisome.   (View pathway)

· Cellular Processes > Cell growth and death > Ferroptosis.   (View pathway)

· Metabolism > Lipid metabolism > Fatty acid biosynthesis.

· Metabolism > Lipid metabolism > Fatty acid degradation.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Fatty acid metabolism.

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Endocrine system > Adipocytokine signaling pathway.


1). Yuan B et al. Activation of SIRT1 Alleviates Ferroptosis in the Early Brain Injury after Subarachnoid Hemorrhage. Oxid Med Cell Longev 2022 Jul 9;2022:9069825. (PubMed: 35855863) [IF=7.310]

2). Kang Y et al. Erythropoietin inhibits ferroptosis and ameliorates neurological function after spinal cord injury. Neural Regen Res 2023 Apr;18(4):881-888. (PubMed: 36204858) [IF=6.058]

3). Sun L et al. Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells. Int J Mol Med 2022 Feb;49(2):17. (PubMed: 34935058) [IF=5.314]

Application: WB    Species: Rat    Sample: H9c2 cells

Figure 3 Fer-1 protects H9c2 cells against Herceptin-induced cell injury and ferroptosis. Fer-1 and DFO reversed the (A) Herceptin-induced reduction in cell viability, (B) Herceptin-induced decrease in GPX4 and SLC7A11 protein expression and Herceptin-induced increase in ACSL4 protein expression. Fer-1 and DFO reversed the Herceptin-induced (C) reduction in GSH content. (D) Fer-1 and DFO did not affect GSSG content. (E) Fer-1 and DFO reversed the Herceptin-induced reduction in the ratio of GSH/GSSG in H9c2 cells. Fer-1 and DFO reversed the Herceptin-induced increase in (F) intracellular and (G) mitochondrial iron levels in H9c2 cells. However, compared with DFO, the effects of Fer-1 were less potent. **P<0.01 and ***P<0.001 vs. NC. #P<0.05 and ##P<0.01 vs. Herceptin (10 µM). Fer-1, ferrostatin-1; GPX4, glutathione peroxidase 4; SLC7A11, recombinant solute carrier family 7 member 11; ACSL4, acyl-CoA synthetase long chain family member 4; GSH, reduced glutathione; GSSG, oxidized glutathione; DFO, deferoxamine; OD, optical density.

Application: WB    Species: rat    Sample: H9c2 cells

Figure 3. | Fer‑1 protects H9c2 cells against Herceptin‑induced cell injury and ferroptosis. Fer‑1 and DFO reversed the (A) Herceptin‑induced reduction in cell viability, (B) Herceptin‑induced decrease in GPX4 and SLC7A11 protein expression and Herceptin‑induced increase in ACSL4 protein expression.

4). Lin D et al. Targeting Ferroptosis Attenuates Inflammation, Fibrosis, and Mast Cell Activation in Chronic Prostatitis. J Immunol Res 2022 Jun 17;2022:6833867. (PubMed: 35755168) [IF=4.493]

Application: WB    Species: Rat    Sample:

Figure 4 DFO and EDA attenuated ferroptosis in EAP model. (a) The iron concentration of prostate lysates was determined by the commercial kit. Results were normalized to protein concentration. (b) The mRNA levels of ferroptosis biomarkers GPX4, SLC7A11, ACSL4, PTGS2, and DHODH relative to internal control were determined by the RT-PCR method. (c) The protein levels of ferroptosis biomarkers GPX4, SLC7A11, ACSL4, LPCAT3, and DHODH were determined by the western blot method. The relative quantification result of each band was performed relative to β-actin. Data was presented as mean ± SEM. #P < 0.05 versus the control group; ##P < 0.01 versus the control group; ###P < 0.001 versus the control group; ∗P < 0.05 versus the EAP group; ∗∗P < 0.01 versus the EAP group; ∗∗∗P < 0.001 versus the EAP group.

5). An JR et al. Liraglutide Alleviates Cognitive Deficit in db/db Mice: Involvement in Oxidative Stress, Iron Overload, and Ferroptosis. Neurochem Res 2021 Sep 4. (PubMed: 34480710) [IF=4.414]

6). Guan S et al. 1, 3‐Dichloro‐2‐propanol induced ferroptosis through Nrf2/ARE signaling pathway in hepatocytes. Environ Toxicol 2022 Jul 23. (PubMed: 35870111) [IF=4.109]

7). Xu W et al. Ferroptosis Plays a Role in Human Chondrocyte of Osteoarthritis Induced by IL-1β In Vitro. Cartilage 2023 Feb 14;19476035221142011. (PubMed: 36786219) [IF=3.117]

8). Ye CL et al. STEAP3 Affects Ferroptosis and Progression of Renal Cell Carcinoma Through the p53/xCT Pathway. Technol Cancer Res Treat Jan-Dec 2022;21:15330338221078728. (PubMed: 35275508) [IF=2.876]

Application: WB    Species: Human    Sample: 786-O and A498 cell

Figure 4. Changes in ferroptosis-related proteins, antioxidant capacity, and lipid peroxidation in 786-O and A498 cell lines. (A, B) Ferroptosis-related proteins were significantly different between siNC group and siSTEAP3 group when treated with erastin. The concentration of erastin is 10 μM (786-O) and 15 μM (A498). (C) MitoSox analysis of reactive oxygen species (ROS) levels in A498 and 786-O cells. (D) Quantification analysis of antioxidant markers in 786-O and A498 cells. (E) Quantification analysis of lipid peroxidation levels in HK-2 cells. All the above data are the mean ± SD from an average of 3 experiments.

9). Miao L et al. Non-classical platinum-based compound 56MESS, with preferential cytotoxic effect on oral cancer cells by downregulating FACL4 expression. Pharmazie 2020 Oct 1;75(10):494-499. (PubMed: 33305724) [IF=1.515]

10). Overexpression of PRDX2 in Adipose-Derived Mesenchymal Stem Cells Enhances the Therapeutic Effect in a Neurogenic Erectile Dysfunction Rat Model by Inhibiting Ferroptosis.

Restrictive clause


Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.